Mithrl Inc.

The scientific decision engine for R&D. Raw data → defensible decisions, faster.

[Mithrl Inc. @mithrl_ai]

Looking forward to #BIO2026 in San Diego!

[Biotechnology Innovation Organization @IAmBiotech]

As we mark 50 years of biotechnology innovation, what conversations are shaping biotech's next chapter? At #BIO2026, explore 135+ sessions across 18 focus areas and hear from the leaders, innovators, policymakers, investors, and patient advocates driving the future of our industry.

View the full program and speaker lineup: https://t.co/Fp2jdXnllw

[Mithrl Inc. @mithrl_ai]

Imagine reducing weeks-long R&D analysis cycles to biologically grounded, defensible insights in a fraction of the time.

Biopharma is generating more multi-modal data than ever before, yet many R&D teams still face fragmented workflows and challenges in turning complex datasets into reproducible scientific decisions.

In our case study, we explore how Mithrl is helping a leading gene therapy biotech transform complex biological data into faster, more defensible decisions through agentic AI, transparent scientific reasoning, and auditable workflows designed for high-stakes R&D environments.

Read more: https://t.co/CPLWTkGgNA

#DrugDiscovery #Oncology #TranslationalResearch #BiomedicalAI

[ASGCT @ASGCTherapy]

Ready to take your research to the next level? Early-career researchers and emerging investigators can secure a $100,000 grant to fund independent pilot studies or advance their professional development in cell and gene therapy.

Don't miss this opportunity to fuel your science and your career. Join ASGCT and apply today!

✔️ Career Development Award: https://t.co/x7aYm6c5AI
✔️ Expanding Pathways Fellowship: https://t.co/Jg4e1S2idD

[Mithrl Inc. @mithrl_ai]

We're in Boston for the Festival of Genomics, Biodata & AI, taking place June 3-4.

Today, June 2, Ada Shaw, PhD, Head of Scientific Partnerships at Mithrl, will be moderating a discussion at the invitation-only Pre-Day PharmAI Leaders Exchange:

Building AI Scientists Can Trust: From Experimental Nuance to Transparent Decisions
🗓 Tuesday, June 2 at 12:00 PM

The session will explore how AI platforms can earn and maintain scientific trust through transparent, traceable reasoning, while helping researchers navigate the complexities of multi-modal data integration and decision-making in biomedical R&D.

Looking forward to conversations with leaders from @bmsnews, @sanofi, @AstraZeneca, @JNJInnovMed, and across AI, genomics, and drug discovery.

Learn more: https://t.co/5UXKA3Kubt

#FOGBoston #BiomedicalAI #DrugDiscovery #MultiOmics #ComputationalBiology #LifeSciences @FLGenomics @ecolienthusiast @msevvana @FischSudeshna

[Mithrl Inc. @mithrl_ai]

National Cancer Survivor Month is a reminder of both how far cancer research has come and the work still ahead.

Today, there are an estimated 18.6 million cancer survivors in the United States, representing approximately 5.4% of the population. By 2040, that number is projected to grow to 26 million.

At Mithrl, we believe that accelerating the path from raw data to biologically grounded, defensible scientific decisions can help move cancer research forward faster and with greater scientific rigor.

As agentic AI continues to shape the future of oncology and translational research, we remain focused on enabling more transparent, reproducible, and auditable approaches to scientific discovery.

Learn more about National Cancer Survivor Month and AACR’s efforts to advance cancer research and survivorship: https://t.co/uxaGf4is2A

#NationalCancerSurvivorMonth #Oncology #CancerResearch #CelebrateSurvivorship @AACR

[Mithrl Inc. @mithrl_ai]

Even after #AACR26 wrapped up, the conversations around AI, multimodal biology, translational research, and precision oncology continue.

The AACR Meeting News recaps provide a strong overview of many scientific sessions, clinical updates, and emerging themes shaping the future of cancer research and drug development.

For those following the latest developments in oncology R&D, these recaps are well worth a read: https://t.co/TueIJGvbVT

#AACR2026 #CancerResearch #PrecisionOncology #DrugDevelopment @AACR

[Mithrl Inc. @mithrl_ai]

Looking forward to #FOGBoston!

[Front Line Genomics @FLGenomics]

Only 5 days to go!

The Festival of Genomics, Biodata & AI is just around the corner – have you got your ticket? Don’t miss this opportunity to learn, connect and be inspired – register now: https://t.co/g5aeMmVIuL #FOGBoston #genomics ##biodata #AI

[Mithrl Inc. @mithrl_ai]

Are you evaluating where AI fits into your R&D organization?

As discovery data across transcriptomics, proteomics, single-cell sequencing, and multi-omics continues to grow, many pharma and biotech teams still face the same challenge: turning complex data into reproducible, defensible scientific decisions.

That’s why trustworthy AI matters, and why Mithrl is building a Scientific Decision Engine designed to support all three pillars of trustworthy AI in scientific R&D.

Learn more and watch the webinar: https://t.co/uTE814DhuK

#AIinBiotech #DrugDiscovery #Bioinformatics #ComputationalBiology #SingleCell #TranslationalResearch #PrecisionMedicine #Omics

[AACR @AACR]

Unprecedented, research-driven advances in cancer immunology over the past two decades have firmly established immunotherapy as the fifth pillar of cancer medicine. Read the @AACR Cancer Progress Report: https://t.co/vx6yJmoRFe

[Mithrl Inc. @mithrl_ai]

We're almost at capacity for this Bay Area event today - AI is reshaping drug development, but where can it deliver meaningful impact?

Today, we’re excited to be at Genentech for the Data Driven Pharma Forum, where leaders from @Genentech, @GileadSciences, and @GSK will discuss the future of AI in pharma R&D.

The conversation will explore how the industry can move beyond AI hype to drive measurable, reproducible outcomes in drug development.

Attendees will also hear from Mithrl Product Manager, Rupert Yip, PhD, who will kick off the event with a live Mithrl tech demo.

🗓 Wednesday, May 27
⏰ 4–8 PM PDT
@Genentech, South San Francisco

We hope to see you there! https://t.co/twLS3w8Wvu

#DataDrivenPharma #AIinPharma #DrugDevelopment

[Mithrl Inc. @mithrl_ai]

Meet Eos, the Scientific Decision Engine for enterprise R&D teams.

Eos helps scientists move from complex omics and multimodal data to reproducible, decision-ready insights faster.

Using agentic AI for biomedical research, Eos enables teams to:
• Automate and scale complex discovery research analysis workflows
• Generate novel insights that are transparent, traceable, and reproducible
• Integrate your knowledge and models within the Eos, fitting into your ecosystem

Learn more: https://t.co/lERVVOKXhD

#DrugDiscovery #BiomedicalAI #TranslationalResearch #Omics #Biotech #LifeSciences #AIinBiotech

[Mithrl Inc. @mithrl_ai]

Happening next week: We’re excited to sponsor the Data Driven Pharma Forum at @genentech on May 27.

This year’s theme takes on a critical question: where do drug development costs really sit, what can AI meaningfully improve, and how do we know if it’s actually working?

Join leaders from Genentech, @GileadSciences, and @GSK for a candid conversation on the evolving role of AI in drug development. Attendees will also hear from Mithrl Co-Founder & CEO Vivek Adarsh, PhD, who will kick off the event with a live Mithrl tech demo.

📍 Genentech, South San Francisco, CA
🗓 Wednesday, May 27, 2026
⏰ 4–8 PM PDT

Register here: https://t.co/twLS3w8Wvu

#DataDrivenPharma #AIinPharma #DrugDevelopment

[Mithrl Inc. @mithrl_ai]

Final day at #BioITExpo in Boston!

It’s been a fantastic week connecting with leaders across biopharma, AI, precision medicine, and biomedical research.

We’ve appreciated everyone who stopped by our booth to meet the Mithrl team, see our platform in action, and discuss the future of AI-driven R&D. It’s also been great engaging with attendees during conference sessions and conversations around AI, bioinformatics, and scientific decision-making.

If you’re attending today, there’s still time to stop by booth #802 before the exhibit hall closes at 2:30 PM.

If you’re unable to make it, you can still request a virtual demo here: https://t.co/lCgDmI3ZSF

#BioITWorld #BioITExpo #Biopharma #PrecisionMedicine #Multiomics #AIinBiotech

[Mithrl Inc. @mithrl_ai]

📢 Happening today at #BioITExpo in Boston: Mithrl team members are leading conversations at the intersection of AI, bioinformatics, and precision medicine.

• Brigitte Ganter, GTM & Product Strategy at Mithrl, is chairing the session “Next-Generation Bioinformatics for Precision Medicine and Cancer Genomics” | 10:15 AM

• Vivek Adarsh, PhD, Co-Founder & CEO at Mithrl, will be participating in two sessions:
– Chairperson’s Remarks: “AI-Enhanced Discovery and Multimodal Insights in Precision Oncology” | 10:15 AM
– Speaking Session: “More Data, Less Insight: Why Scientific AI Needs a New Framework" | 2:30 PM

If you’re attending #BioITExpo, stop by booth #802 for a free ice cream treat and to connect with the Mithrl team about transparent, reproducible AI for biopharma R&D.

#BioITWorld #BioIT2026 #PrecisionMedicine #Bioinformatics @bioitworld @brigittegs @flyingthor

[Mithrl Inc. @mithrl_ai]

Don’t miss Vivek Adarsh, PhD, Co-Founder & CEO of Mithrl, at #BioITExpo on Wednesday, May 20:

• Chairing “AI-Enhanced Discovery and Multimodal Insights in Precision Oncology” at 10:15 AM (Track T7: AI for Oncology, Precision Medicine, and Health)

• Speaking on “More Data, Less Insight: Why Scientific AI Needs a New Framework” at 2:15 PM (Track T7: AI for Oncology, Precision Medicine, and Health)

[Mithrl Inc. @mithrl_ai]

Precision oncology is generating more data than ever across genomics, transcriptomics, imaging, spatial biology, and clinical outcomes.

But more data doesn’t automatically create better insight.

Many research teams still face fragmented workflows, delayed analysis, and limited transparency in how conclusions are reached, making reproducibility and scientific trust difficult to achieve at scale.

As AI adoption accelerates across biopharma R&D, the challenge is no longer just speed. It’s generating reproducible, reviewable, and scientifically defensible insights from complex multimodal data.

In our latest article, Vivek Adarsh, PhD, Co-Founder & CEO of Mithrl, explores why precision oncology remains rich in data but poor in insight, and how transparent scientific AI may help bridge the gap.

Read more: https://t.co/YxgMazM6rW

#PrecisionOncology #AIinBiotech #CancerResearch #Bioinformatics #PrecisionMedicine #DrugDiscovery #BioITExpo @bioitworld @flyingthor

[Mithrl Inc. @mithrl_ai]

We’re back in Boston this week for #BioITExpo, continuing the conversation around AI, biomedical research, and data-driven discovery.

📍 Stop by Booth #802 for a free ice cream treat and a live look at Mithrl’s Scientific Decision Engine for biomedical and biopharma R&D teams.

Members of the Mithrl team will also be speaking and chairing sessions throughout the conference.

🧬 See how Mithrl enables:
• Transparent, verifiable AI for biomedical research
• Reproducible analysis across multimodal datasets
• Multi-agent workflows for biopharma R&D
• Natural language interaction with complex scientific data

#BioITWorld #Biopharma #DrugDiscovery #Multiomics #AIinBiotech @bioitworld

[Mithrl Inc. @mithrl_ai]

Come see us at booth #802 for a live look at Mithrl’s Scientific Decision Engine for biomedical and biopharma R&D teams. #BioITExpo

[Bio-IT World @bioitworld]

#BioITExpo starts next week in Boston.

Reserve your spot today to join the Software Applications & Services Track and learn how leaders are building scalable, compliant, AI-ready software platforms for life sciences R&D.

Cloud-native architecture, interoperability, governance & modernization strategies—all in one program. https://t.co/18Av3ftNWX

[Mithrl Inc. @mithrl_ai]

Bioinformatics is at a crossroads. The life sciences industry is generating more biological data than ever before, yet turning that data into reproducible, clinically meaningful insight remains one of the field’s greatest challenges.

The bottleneck is no longer data generation. It’s insight generation.

In our latest article, Brigitte Ganter, GTM & Product Strategy at Mithrl, explores the growing challenges surrounding multi-omics complexity, reproducibility, AI adoption, and the “final mile” between computational discovery and real-world clinical impact.

As Bio-IT World approaches, these conversations are becoming increasingly important for the future of precision medicine and biopharma R&D.

Read the full article: https://t.co/myHCQgauDg

#BioITExpo #Bioinformatics #PrecisionMedicine #Biopharma @brigittegs @bioitworld